Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 105 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 Respuestas a sus preguntas sobre la vacuna contra el COVID-19 March 12, 2021 Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer October 19, 2018 FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular... February 11, 2021 Load more HOT NEWS Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer Man Who Lost His Mother to Breast Cancer Opens Resource Center... EMA Recommends Granting a Marketing Authorisation for Generic Eribulin Understanding FDA Emergency Use Authorization
